Search

The article discusses how several chemists downsized out from big pharmaceutical companies are finding new careers with contract research organizations in the U.S. Many Western chemical companies are reconsidering the way they conduct research. Many are closing down their research and development laboratories and are employing contract research organizations. Some of chemists who are finding work with contract research organizations are Yanping Chen, John Perumattam and Bill Smith.

Focuses on pharmaceutical outsourcing in the United States. List of top contract manufacturers; Emphasis on commercial-scale manufacturing; Development agreement between DSM and GelTex Pharmaceuticals Inc.

Focuses on the participation of drug manufacturers on the contract manufacturing market. Growth in the sales of custom synthesis of Merck; Concentration of Boehringer Ingelheim Chemicals on active pharmaceutical ingredient manufacturing; Participation of GlaxoSmithKline in chemical synthesis plant selling.

Reports on the biocatalytic expertise of fine chemical makers which meets the needs of pharmaceutical customers. Biotacalysis in research efforts; Synthesis techniques that yield single-enantiomer compounds.

Focuses on the need for commercial-scale pharmaceutical chemical outsourcing services in the United States. Alliance between development-stage drugmaker and manufacturers; Plans of drug companies to develop an early-phase business in-house; Relevance of implementing toxicological studies. INSETS: Some Seek To Develop An Early-Phase Business In-House.;Helping People Do Business For 75 Years..

Reports on the proliferation of biopharmaceutical contract manufacturing in the United States. Survey conducted by Pharmaceutical Research & Manufacturers of America; Clinical testing phase of biotechnology-based drugs; Forecast of an increase in the number of biotech drugs in the country; Need for contract manufacturers to invest in production capacity.

The article discusses the growth of the global market for building-block chemicals (BBC) for drug discovery. A background on the history of the emergence of the BBC business is provided. The growth was attributed to the increasing demand for BBC worldwide. Among the companies that are providing drug makers with BB to build targeted libraries are Ukraine-based Enamine and U.S.-based TransTech.

The article discusses an alternative job for laid-off British chemists. As big pharmaceutical companies in Britain such as GlaxoSmith Kline, AstraZeneca, and Merck & Co. began laying off research and development personnel and shutting down research facilities, out-of-job chemists have a place to find work through the contract research organizations (CROs). CROs provide services to pharmaceutical industry clients ranging from structural biology to absorption, distribution, metabolism and excretion (ADME) studies.

The article presents a case study regarding the collaboration between U.S.-based biopharmaceutical start-up firm Ilypsa Inc. and German custom manufacturer Saltigo to develop polymeric pharmaceutical products. The partnership with Saltigo allows Ilypsa to take advantage of the other firm's skills in the field of multi-step chemical synthesis. According to German polymer chemist and Ilypsa's chief business officer Gerrit Klaerner, they wanted to provide solutions to life-threatening diseases.

Focuses on the focus of chemical company exhibitors at the Informex custom manufacturing trade show in Las Vegas, Nevada on new kilogram-scale facilities for small quantities of drug compounds made under current Good Manufacturing Practice standards. Question whether the overcapacity plaguing the large-volume end of the custom manufacturing business will migrate to the small-scale end; Reference to companies that are poised to expand its operations; Extension of the Informex theme of kiloscale manufacturing into the nonpharmaceutical realm.

Reports on the use of foreign resources by pharmaceutical chemistry services companies in the United States. Reasons of companies for hiring foreign chemists; Nature and extent of partnerships formed by drug companies with foreign firms.

Details industrial enzymes manufacturer, Genencor International's plan to enter the health care business in the United States. Manufacture of products for pharmaceutical companies; Company's expertise in biotechnology; Challenges facing the company in replicating its success in expressing effective strains of enzymes.

Reports on the emergence of the simulated moving bed (SMB) technology for pharmaceutical chemical manufacturing processes. Features of the technology; Chemical companies using the technique; Comparison with the high-performance liquid chromatography technique.

Reports on the effort of Cambrex Corp. to become one of the leading suppliers of active ingredients, intermediates and service to the global pharmaceutical industry. Development of a plan to expand in the fine chemicals business; Acquisition of companies; Purchase of Irotec.

The article discusses plans of the Merck KGaA to leave the over-the-counter (OTC) drug business. It mentions Merck's OTC business markets products such as Bion vitamins and Seven Seas cod liver oil. It also mentions Johnson & Johnson has long run an OTC business with brands such as Tylenol and Benadryl. It also mentions Sanofi acquired the Chattem in 2010.

The article reports on the decisions of several top researchers to leave academic and government posts for jobs in the pharmaceutical industry. Drug company Novartis hired Mark C. Fishman, a Harvard Medical School professor, as the president of its Novartis Institutes for BioMedical Research (NIBR) in Cambridge, Massachusetts. Ron Malachuk, a principal at executive search firm Korn Ferry, attributed the trend to efforts of drugmakers to develop intellectual property and increase innovation.

The article reports that pharmaceutical chemical company CordenPharma would acquire a high containment active pharmaceutical ingredient (API) facility from Pfizer in Boulder, Colorado.

The article reports that AkzoNobel has completed expansion of the plant in Mariager, Denmark, which is into making of pharmaceutical-grade salt. The project increases the capacity by 60% and the main market for drug-grade salt is dialysis solutions. Views of Nils van der Plas,general manager of AkzoNobel's on the issue is presented.

The article reports on the launch of cancer drug company Tango Therapeutics by venture capital firm Third Rock Ventures in Cambridge, Massachusetts.

Information about the chemistry outsourcing of drug companies discussed at a conference and trade show "ChemOutsourcing," held in Long Branch, New Jersey in September 2009 is presented. Topics include the differences between big pharmaceutical companies and biotechnology firms in terms of hiring process of pharmaceutical chemistry partners. It featured several executives including Firoz D. Antia of Palatin Technology and David Fick of Senomed Biosciences, California.

The article discusses the slow movement of pharmaceutical industries back in the U.S. The author notes that several companies are relocating their operation in China after citing that it has lesser expenditures in manpower. However, companies are also downsizing their manpower and operation after the recession hit the marketplace.

The article reports on the success of the global biopharmaceutical industry in 2006 as evidenced by increased in product sales, total revenues and earnings. Acquisitions were also made by biopharmaceutical companies. Eli Lilly & Co. bought Icos in January 2006. The product sales of Genentech surpassed $2 billion in its first quarter.

The article focuses on the partnership between Adherex Technologies Inc. and Scynexis Inc. Lacking an in-house chemistry capabilities, Adherex has not able to develop a follow-on to its lead drug candidate, ADH-1. Because of Scynexis' chemistry skills, Adherex signed a deal with the company that allowed it to tackle small-molecule N-cadherin antagonists in earnest.

The article reports on Midwest, which is some kind of a precious stone in the pharmaceutical chemical world. Midwest is considered as the home to various small but flourishing companies that ascribe a good part of their success to their midwestern location. Through these companies, the U.S. pharmaceutical chemical business is noticeably active and good.

Reports on the financial performance of Pfizer Inc., the world's largest drug company, for the third quarter of 2005. Factors contributing to the decline in the sales of Pfizer; Decrease in revenues; Total earnings.

Reports on the application of developed tools for the drug industry by Symyx Inc. to accelerate research on new materials in the U.S. Initiation of highthroughput experimentation; Statement of CEO Steven D. Goldby and president Isy Goldwasser regarding the goal of the company; Development of electronic laboratory notebooks as a replacement to the hardcover ledgers used by scientists.

Focuses on the slowdown in the second-quarter earnings in the core pharmaceutical businesses of big U.S. drug companies, due to patent expirations and product recalls. Better performance of European drug-makers compared to their U.S. counterparts; Comparison of the earnings of U.S. and European drug companies; Rise in the earnings of Wyeth Laboratories Inc. as well as Johnson & Johnson, while that of Pfizer and Merck & Co. Inc., plunged.

Reports on the financial performance of the biopharmaceutical industry in the United States for the first quarter of 2005. Revenues; Earnings; Profit margin; Industry leader; Protein Design Labs Inc.'s loss.

Reports on the financial performance of the pharmaceutical industry in the United States and Europe for the first-quarter of 2005. AstraZeneca PLC's growth leader; Johnson and Johnson Inc. and Pfizer Inc.'s strong performers; Increase in Wyeth Laboratories Inc.'s sales and earnings; Profit margin.

Focuses on Lexington, Massachusetts-based Critical Therapeutics' launch of its asthma drug, zileuton, with the help of pharmaceutical services firm Rhodia Pharma Solutions. Obtainment of U.S. Food and Drug Administration approval of the third-party plant where the finished formulation will be made; Need for submitting the Supplemental New Drug Application by the end of the first quarter of 2005; Rhodia's achievement in manufacturing all the zileuton required for registration batches.

Reports on the state of chemical companies that supply oligonucleotides to the pharmaceutical industry. Continuous hiring of chemical companies by drug firms in the early phases of development for their small-volume oligonucleotides needs; Avecia Biotechnology Inc.'s deal with Acuity Pharmaceuticals to manufacture oligonucleotides; Impact to the chemical industry of the U.S. Food and Drug Administration's announcement that the oligonucleotide-based drug candidate of La Jolla Pharmaceutical Co. need another multiyear study before it could be approved.

Discusses the evolution of combinatorial chemistry. Role of combinatorial chemistry in drug discovery; High-throughput screening of combinatorial chemistry libraries to find drug candidates; Evolution of combinatorial techniques at companies that supply compound libraries to other firms.

Focuses on the status of pharmaceutical fine chemicals outsourcing in Japan. Details on the market for the fine chemical makers; Changes to Japan's Pharmaceutical Affairs Law; Ability of the Japanese pharmaceutical industry to evaluate drug candidates.

Reports on the pharmaceutical chemicals firms for drug industry in Canada. Overview of the first firm to make pharmaceutical chemicals for third parties; Business plans of Delmar Chemicals on acquiring process chemistry and engineering expertise; Acquisition of Delmar by Roemmers.

Reports on Rhodia's acquisition of ChiRex, which signaled the company's entry into the advanced pharmaceuticals business. Formation of Rhodia ChiRex, as one of three Rhodia pharmaceutical units; Companies' synergies in pharmaceutical chemical manufacturing.

The article reports that the revamp of major pharmaceutical companies' research and development (R&D) programs is affecting biotechnology industry partners. Merck & Co. has returned all rights to betrixaban, a Factor Xa inhibitor anticoagulant, to Portola Pharmaceuticals as part of its ongoing prioritization of the late-stage pipeline. Also affected by the portfolio reassessment is the partnership between GlaxoSmithKline and Targacept.

The article reports on the acquisition of Stiefel Laboratories by GlaxoSmithKline (GSK), a maker of dermatology dugs as part of its diversification in the U.S. GSK acquires the Stiefel for $2.9 billion plus $400 million in debt and possible $300 million cash payment. Chief executive officer Andrew Witty states that acquisition fits the strategy of the its plan to grow and diversify. GSK is considered one of the big pharmaceutical makers of the industry that ventures in diversification.

The article reports on the plan of biotechnology company Amgen Inc. to acquire two small firms that are developing chemistry-based drugs. The company will pay $420 million to purchase Ilypsa Inc. and $300 million to acquire Alantos Pharmaceuticals Inc. Ilypsa is a four-year-old firm that is developing a treatment for excess phosphorus in patients with chronic kidney disease. Meanwhile, Alantos Pharmaceuticals develops a dipeptidyl peptidase IV inhibitor for the treatment of type two diabetes.

The article reports on the move of AstraZeneca PLC of Great Britain to acquire MedImmune Inc. for about $ 15.6 billion, as a part of the firm's push into protein-based therapeutics. It was cited that MedImmune is a formidable presence in the biotechnology industry, with a revenue of $ 1.3 billion and earnings of $ 75 million in 2006. John Patterson, the company's Executive Director cites that the deal will increase the proportion of biologics in the firm's pipeline from 7 percent to 27 percent.

The article reports on the move of Bayer Schering Pharma to close its two major research laboratories in the U.S. The said closure will affect about 600 positions, specifically in the pharmaceutical research and development department. However, Bayer is working out for its new research and development organization where research that are conducted in several sites will be consolidated into its three major research and development centers worldwide.

The article reports on the intent of Abbott Laboratories Inc. for the acquisition of Kos Pharmaceuticals Inc., a specialty drugmaker in Cranbury, New Jersey. Such move will enable Abbott Laboratories to expand its presence in the lipid management field. Furthermore, the acquisition has been aimed to develop TriCor, a lipid management drug and compete with the leading lipid management drugs from various drugmaker companies.

The article reports on the acquisitions made by pharmaceutical companies, Sanofi-Aventis SA and Ranbaxy Laboratories Ltd., in Europe. Sanofi, which has just acquired 24.9 percent interest of Czech generic company, Zentiva AS, refers the move as part of its strategy to expand in Central and Eastern Europe. On the other hand, Ranbaxy will pay Advent International Corp. for a 97 percent stake in Terapia.

Reports on the decision of Chiron Corp. to accept the offer of Novartis Corp. to acquire some of Chiron's stock shares in the U.S. Views of Novartis CEO, Daniel Vasella regarding his plan for Chiron; Reasons of Novartis on the acquisition of the shares of Chiron; Business forecast of Novartis for the global vaccine market in the next few years.

Reports that Lonza Inc. and UCB Chemicals Corp. have signed a long-term agreement under which Lonza will manufacture active pharmaceutical ingredients based on PEGylated antibody fragments for UCB. Worth of microbial fermentation facility in Visp, Switzerland; Growth in the fields of antibody fragments and single-chain antibodies; Advantage of microbial production; Clinical trials of antibody fragment for Crohn's disease and rheumatoid arthritis.

Reports on the earnings forecast of Pfizer CEO Hank McKinnell for 2005 and 2006. Withdrawal of cyclooxygenase-2 pain reliever Bextra from the U.S. and European markets; Cost-cutting initiatives of the company.

Focuses on the expectation of Chiral Technologies Inc., a supplier of chiral stationary-phase media and chromatography services to the pharmaceutical industry, of a growth in sale by more than 25% for 2004. Decision of Cephalon, a biopharmaceutical company with a strategy of acquiring late-stage or already marketed drugs; Significance on the launch of Provigil, a drug for narcolepsy; Statement of Nelson Landmesser, a senior Cephalon scientist working in chemical process development.

Focuses on Ernst & Young Inc.'s report about the pharmaceutical industry in the United States. Public's dissatisfaction with high drug prices; Weak industry earnings; Industry executives' action to address the regulatory compliance issues companies face.

Reports on the efforts of fine chemicals producer Sigma-Aldrich to improve its image. Plans to boost company's role in custom manufacturing; Effort to erase the company's image in the drug industry as a mere supplier of lab chemicals; Acquistion of contract drug development chemistry supplier Ultrafine in April 2004.

Examines the expansion plans of pharmaceutical fine chemicals manufacturer Clariant. Percentage expansionof the small-scale facilities in the company's small-scale facilities in Springfield, Missouri; Successful management of the company's far-flung assets.

Presents case studies on the outsourcing relationship between a drug companies and pharmaceutical chemical suppliers. Reward for companies that provide good service with follow-up business from their drug industry partners; Partnership between Allos Therapeutics and Hovione; Fermentation project by Biosynexus and Avecia.